The myokine FGF21 associates with enhanced survival in ALS and mitigates stress-induced cytotoxicity
Preprint
Abstract
Amyotrophic lateral sclerosis (ALS) is an age-related and fatal neurodegenerative disease characterized by progressive muscle weakness. There is marked heterogeneity in clinical presentation, progression, and pathophysiology with only modest treatments to slow disease progression. Molecular markers that provide insight into this heterogeneity are crucial for clinical management and identification of new therapeutic targets. In a prior muscle miRNA sequencing investigation, we identified altered FGF pathways in ALS muscle, leading us to investigate FGF21. We analyzed human ALS muscle biopsy samples and found a large increase in FGF21 expression with localization to atrophic myofibers and surrounding endomysium. A concomitant increase in FGF21 was detected in ALS spinal cords which correlated with muscle levels. FGF21 was increased in the SOD1 G93A mouse beginning in presymptomatic stages. In parallel, there was dysregulation of the co-receptor, β-Klotho. Plasma FGF21 levels were increased and high levels correlated with slower disease progression, prolonged survival, and increased body mass index. In NSC-34 motor neurons and C2C12 muscle cells expressing SOD1 G93A or exposed to oxidative stress, ectopic FGF21 mitigated loss of cell viability. In summary, FGF21 is a novel biomarker in ALS that correlates with slower disease progression and exerts trophic effects under conditions of cellular stress.Keywords
This publication has 93 references indexed in Scilit:
- Higher Glycemic Index and Glycemic Load Diet Is Associated with Slower Disease Progression in Amyotrophic Lateral SclerosisAnnals of Neurology, 2023
- Fibroblast growth factor-21 alleviates proteasome injury via activation of autophagy flux in Parkinson’s diseaseExperimental Brain Research, 2023
- Altered Bioenergetics and Metabolic Homeostasis in Amyotrophic Lateral SclerosisNeurotherapeutics, 2022
- Neuromuscular Junction Dysfunction in Amyotrophic Lateral SclerosisMolecular Neurobiology, 2022
- Behavioral, Hormonal, Inflammatory, and Metabolic Effects Associated with FGF21-Pathway Activation in an ALS Mouse ModelNeurotherapeutics, 2020
- Fibroblast growth factor 21 controls mitophagy and muscle massJournal of Cachexia, Sarcopenia and Muscle, 2019
- Fibroblast Growth Factor 21 (FGF21) Promotes Formation of Aerobic Myofibers via the FGF21‐SIRT1‐AMPK‐PGC1α PathwayJournal of Cellular Physiology, 2017
- ALS biomarkers for therapy development: State of the field and future directionsMuscle & Nerve, 2015
- Smads as muscle biomarkers in amyotrophic lateral sclerosisAnnals of Clinical and Translational Neurology, 2014
- Characterization of early pathogenesis in the SOD1G93A mouse model of ALS: part II, results and discussionBrain and Behavior, 2013